Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vet associations criticise CMA’s remedies
The organisations say the 'remedies' will impact independent practices.
BVA, BSAVA, BVNA, SPVS and VMG have submitted a joint response.

A number of major veterinary organisations have united to criticise proposed ‘remedies’ set out by the Competition and Markets Authority (CMA).

In a full response to the working paper, the British Veterinary Association (BVA) expresses ‘serious concerns’ for the suggested remedies. It describes the measures as ‘completely disproportionate’ to the issues they seek to address.

The response is a joint submission from the BVA, the British Small Animal Veterinary Association, the British Veterinary Nursing Association, the Society of Practising Veterinary Surgeons and the Veterinary Management Group.

Among the concerns is the proportionality of the remedies. The organisations suggest the remedies are ‘too extensive’ in relation to the CMA’s concerns, placing administrative burden on the practices.

They say this would disproportionately impact smaller, independent practices, which would have limited capacity and resources.

The response particularly raises concern about the financial cost the remedies could have, with many of the changes requiring new technology solutions. This could again affect independent practices, which may be forced to pass the costs onto their clients.

By extension, the organisations say that these increased costs could have a negative impact on animal welfare as a whole. As increased costs result in higher veterinary fees, pet owners may delay or avoid taking their pets to veterinary practices.

The BVA says that, while it supports a standardised price list, CMA’s proposed approach is ‘too complex’ and unworkable. It says practices would be required to provide detail which is ‘overly burdensome’ and does not increase clarity for clients.

It also criticises suggestions of price control on medication, which it believes will reduce the availability of products, harming consumer choice and animal welfare.

Elizabeth Mullineaux, BVA president, said: “If all the measures were implemented at the same time, the sheer volume and complexity would place an unacceptable burden on vet practices and could jeopardise the viability of many businesses, particularly smaller independent practices.

“This could have the unintentional consequence of reducing consumer choice and potentially increasing vet fees, which could in turn negatively impact animal health and welfare – precisely the opposite of what the CMA is trying to achieve.”

BVA, BSAVA, BVNA, SPVS and VMG’s full response to the working paper can be found here.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.